Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

Edara, Venkata-Viswanadh, Pinsky, Benjamin A., Suthar, Mehul S., Lai, Lilin, Davis-Gardner, Meredith E., Floyd, Katharine, Flowers, Maria W., Wrammert, Jens, Hussaini, Laila, Ciric, Caroline Rose, Bechnak, Sarah, Stephens, Kathy, Graham, Barney S., Bayat Mokhtari, Elham, Mudvari, Prakriti, Boritz, Eli, Creanga, Adrian, Pegu, Amarendra, Derrien-Colemyn, Alexandrine, Henry, Amy R., Gagne, Matthew, Douek, Daniel C., Sahoo, Malaya K., Sibai, Mamdouh, Solis, Daniel, Webby, Richard J., Jeevan, Trushar, Fabrizio, Thomas P.·2021·New England Journal of Medicine
DOI 10.1056/nejmc2107799

Cited by (332)

Items 201–300 of 332

  1. Scalable Inhibitors of the Nsp3–Nsp4 Coupling in SARS-CoV-2
    Abdul‐Rahman Azizogli, Varun Pai, Francesco Coppola, Roya Jafari, Joseph Dodd‐o, Rohan Harish, Bhavani Balasubramanian, Jatin Kashyap, Amanda M. Acevedo‐Jake, Petr Král et al. · 2023 · ACS Omega
  2. Cross-reactive humoral and CD4+ T cell responses to Mu and Gamma SARS-CoV-2 variants in a Colombian population
    Fabiola Martel, Juliana Cuervo-Rojas, Juana Ángel, Beatríz Ariza, John Mario González, Carolina Ramírez-Santana, Yeny Acosta‐Ampudia, Luisa Fernanda Murcia-Soriano, Norma Montoya, Claudia Cecilia Cardozo-Romero et al. · 2023 · Frontiers in Immunology
  3. Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: implications of immune imprinting and interference
    Min Joo Choi, Young Jun Yu, Jae‐Weon Kim, Hea Jeon Ju, So Youn Shin, Yun-Jung Yang, Hee Jin Cheong, Woo Joo Kim, Chulwoo Kim, Hwa Jung Kim et al. · 2024 · Clinical Microbiology and Infection
  4. Increased Antibody Avidity and Cross-Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Variants by Hyperimmunized Transchromosomic Bovine–Derived Human Immunoglobulins for Treatment of Coronavirus Disease 2019
    Juanjie Tang, Gabrielle Grubbs, Youri Lee, Hua Wu, Thomas C Luke, Kristi A. Egland, Christoph L Bausch, Eddie J. Sullivan, Surender Khurana · 2022 · The Journal of Infectious Diseases
  5. COVID-19 booster vaccination during pregnancy enhances maternal binding and neutralizing antibody responses and transplacental antibody transfer to the newborn (DMID 21-0004)
    Flor M. Muñoz, Christine M. Posavad, Barbra A. Richardson, Martina L. Badell, Katherine E. Bunge, Mark J. Mulligan, Lalitha Parameswaran, Clifton W. Kelly, Courtney Olsen-Chen, Richard Novák et al. · 2022 · medRxiv
  6. A novel fast hybrid capture sequencing method for high-efficiency common human coronavirus whole-genome acquisition
    Zixinrong Meng, Shuo Wang, Liping Yu, Kangchen Zhao, Tao Wu, Xiaojuan Zhu, Ning Yang, Qiao Qiao, Junyan Ma, Bin Wu et al. · 2024 · mSystems
  7. In Silico Genome Analysis Reveals the Evolution and Potential Impact of SARS-CoV-2 Omicron Structural Changes on Host Immune Evasion and Antiviral Therapeutics
    Dhruv Chauhan, Nikhil Chakravarty, Arjit Vijey Jeyachandran, Akshaya Jayakarunakaran, Sanjeev Sinha, Rakesh K. Mishra, Vaithilingaraja Arumugaswami, Arunachalam Ramaiah · 2022 · Viruses
  8. Thromboembolism after Astra Zeneca COVID-19 vaccine: Not always PF4- antibody mediated
    Sascha d’Almeida, Sinisa Markovic, Patrick Christian Hermann, Hendrik Bracht, Johannes Peifer, Thomas Jens Ettrich, Armin Imhof, Shaoxia Zhou, Manfred Weiss, Andreas Viardot et al. · 2023 · Human Vaccines & Immunotherapeutics
  9. Analysis of SARS-CoV-2 variants B.1.617: host tropism, proteolytic activation, cell–cell fusion, and neutralization sensitivity
    Li Zhang, Qianqian Li, Jiajing Wu, Yuanling Yu, Yue Zhang, Jianhui Nie, Ziteng Liang, Zhimin Cui, Shuo Liu, Haixin Wang et al. · 2022 · Emerging Microbes & Infections
  10. Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2
    Harini Natarajan, Shiwei Xu, Andrew R. Crowley, Savannah E. Butler, Joshua A. Weiner, Evan M. Bloch, Kirsten E. Littlefield, Sarah E. Benner, Ruchee Shrestha, Olivia Ajayi et al. · 2022 · BMC Immunology
  11. Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications
    Congshan Jiang, Kaichong Jiang, Xiaowei Li, Ning Zhang, Wenhua Zhu, Liesu Meng, Yanmin Zhang, Shemin Lu · 2022 · Journal of Pharmaceutical Analysis
  12. Insights into organoid-based modeling of COVID-19 pathology
    Mohadese Hashem Boroojerdi, Tariq Al Jabry, Seyed Mohamad Javad Mirarefin, Halima M. A. Albalushi · 2023 · Virology Journal
  13. A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo
    Fanlin Li, Wei Xu, Xiaoqing Zhang, Wanting Wang, Shan Su, Ping Han, Haiyong Wang, Yanqin Xu, Min Li, Lilv Fan et al. · 2023 · Communications Biology
  14. Variable neutralizing antibody responses to 10 SARS-CoV-2 variants in natural infection with wild- type (B.1) virus, Kappa (B.1.617.1), and Delta (B.1.617.2) variants and COVISHIELD vaccine immunization in India: utility of the MSD platform
    Rajashree Patil, Sonali Hemant Palkar, Akhileshchandra Mishra, Rahul Patil, Vidya Avinash Arankalle · 2023 · Frontiers in Immunology
  15. A bioengineered pseudovirus nanoparticle displaying SARS‐CoV 2 RBD fully protects mice from mortality and weight loss caused by SARS‐CoV 2 challenge
    Ming Xia, Krisangel López, Frank S. Vago, Pengwei Huang, Dawn I. Auguste, Wen Jiang, Albert J. Auguste, Ming Tan · 2023 · Biotechnology Journal
  16. Community transmission of SARS-CoV-2 during the Delta wave in New York City
    Katherine Dai, Steffen Foerster, Neil M. Vora, Kathleen Blaney, Chris Keeley, Lisa Hendricks, Jay K. Varma, Theodore G. Long, Jeffrey L. Shaman, Sen Pei · 2023 · BMC Infectious Diseases
  17. Covaxin (BBV152) Vaccine Neutralizes SARS-CoV-2 Delta and Omicron variants
    Venkata Viswanadh Edara, Mit Patel, Mehul S. Suthar · 2022 · medRxiv
  18. Dual Inhibition of Cathepsin L and 3CL-Pro by GC-376 Constrains SARS Cov2 Infection Including Omicron Variant
    Prabhakaran Kumar, Kiira M Ratia, Justin M. Richner, Gregory R. J. Thatcher, Rashmi Kadam, Sandra Paulina Smieszek, Bartlomiej P. Przychodzen, Vuk Koprivica, Gunther Birznieks, Mihael H. Polymeropoulos et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  19. A Global Collaborative Comparison of SARS-CoV-2 Antigenicity Across 15 Laboratories
    Polina Brangel, Sina Türeli, Barbara Mühlemann, Nicole Liechti, Daniel Zysset, Olivier B. Engler, Isabel Hunger‐Glaser, Ioana Ghiga, Giada Mattiuzzo, Isabella Eckerle et al. · 2024 · Viruses
  20. Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti–SARS-CoV-2 antibodies in the absence of CXCL13
    Marne Azarias-da-Silva, Pierre Nioche, Calaiselvy Soudaramourty, Anne Bull-Maurer, Mounira Tiouajni, Dechuan Kong, Ouafa Zghidi‐Abouzid, Morgane Picard, Ana Mendes‐Frias, André Santa Cruz et al. · 2023 · Science Advances
  21. Neutralization Heterogeneity of Circulating SARS-CoV-2 Variants to Sera Elicited by a Vaccinee or Convalescent
    Meng Zhang, Yixin Gong, Shunchang Jiao · 2022 · Future Virology
  22. Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants
    Eric Ji Da Wang, Arup K. Chakraborty · 2022 · PLoS Computational Biology
  23. Distinct neutralizing kinetics and magnitudes elicited by different SARS-CoV-2 variant spikes
    Yang Liu, Jianying Liu, Jing Zou, Ping Ren, Scott C. Weaver, Xuping Xie, Pei‐Yong Shi · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  24. Altered baseline immunological state and impaired immune response to SARS-CoV-2 mRNA vaccination in lung transplant recipients
    Mengyun Hu, Ana Paula B N Oliveira, Zhuoqing Fang, Yupeng Feng, Molly Miranda, Sangeeta Kowli, Prabhu S. Arunachalam, Gowri Vasudevan, Harold Sai-yin Hui, Alba Grifoni et al. · 2025 · Cell Reports Medicine
  25. Immunotherapy and CRISPR Cas Systems: Potential Cure of COVID-19?
    Xuesong He, Xiao Xue Zeng · 2022 · Drug Design Development and Therapy
  26. Anti-SARS-CoV-2S Antibody Levels in Healthcare Workers 10 Months after the Administration of Two BNT162b2 Vaccine Doses in View of Demographic Characteristic and Previous COVID-19 Infection
    Blanka Wolszczak-Biedrzycka, Anna Bieńkowska, Joanna Ewa Zaborowska, Elwira Smolińska-Fijołek, Grzegorz Biedrzycki, Justyna Dorf · 2022 · Vaccines
  27. Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview
    Nastaran Hadizadeh, Mousa Naderi, Jafar Khezri, Meysam Yazdani, Mehdi Shamsara, Ehsan Hashemi · 2022 · Journal of Diabetes & Metabolic Disorders
  28. Antibody Binding and Neutralization of Live SARS-CoV-2 Variants Including BA.4/5 Following Booster Vaccination of Patients with B-cell Malignancies
    Andrés Chang, Akil Akhtar, Lilin Lai, Victor Manuel Orellana-Noia, Susanne L. Linderman, Ashley A. McCook‐Veal, Jeffrey M. Switchenko, Manpreet Saini, Rajesh M. Valanparambil, Kristie A. Blum et al. · 2022 · Cancer Research Communications
  29. Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation
    Li Fu, Dean Gilham, Stephanie C. Stotz, Christopher D. Sarsons, Brooke D. Rakai, Laura M. Tsujikawa, Sylwia Wasiak, Jan O. Johansson, Michael Sweeney, Norman C.W. Wong et al. · 2023 · International Immunopharmacology
  30. Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in nonhuman primates is coincident with an anamnestic antibody response in the lower airway
    Matthew Gagné, Kizzmekia S. Corbett, Barbara J. Flynn, Kathryn E. Foulds, Danielle A. Wagner, Shayne F. Andrew, John-Paul M. Todd, Christopher Cole Honeycutt, Lauren McCormick, Saule T. Nurmukhambetova et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  31. Spatiotemporal evolution and transmission dynamics of Alpha and Delta SARS-CoV-2 variants contributing to sequential outbreaks in Cambodia during 2021
    Yvonne C. F. Su, Michael A. Zeller, Tey Putita Ou, Jordan Ma, Leakhena Pum, Rong Zhang, Sophannadeth Rath, Vireak Heang, Sonita Kol, Reaksa Lim et al. · 2024 · Communications Medicine
  32. Serological response and immune‐related adverse events following COVID‐19 vaccination in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta‐analysis
    Yue Wang, Dong Chen, Yuancan Pan, Haiming Li, Weizhe Zhao, Taicheng Lu, Weijia Kong, Min Ding, Xiaomin Wang, Gan‐Lin Zhang · 2023 · Reviews in Medical Virology
  33. [Retracted] A Bioinformatics Approach for the Prediction of Immunogenic Properties and Structure of the SARS‐COV‐2 B.1.617.1 Variant Spike Protein
    Dr. Vijay Kumar Srivastava, Sanket Kaushik, Gazal Bhargava, Ajay Jain, Juhi Saxena, Anupam Jyoti · 2021 · BioMed Research International · Retracted
  34. Trajectories of Seroprevalence and Neutralizing Activity of Antibodies against SARS-CoV-2 in Southern Switzerland between July 2020 and July 2021: An Ongoing, Prospective Population-Based Cohort Study
    Rebecca Amati, Giovanni Piumatti, Giovanni Franscella, Peter Buttaroni, Anne-Linda Camerini, Laurie Corna, Sara Levati, Marta Fadda, Maddalena Fiordelli, Anna Maria Annoni et al. · 2023 · International Journal of Environmental Research and Public Health
  35. Paradigm of immune dysregulation in coronavirus disease-2019 infection
    Om Saswat Sahoo, Karthikeyan Pethusamy, Arnab Nayek, Rashmi Minocha, Ruby Dhar, Subhradip Karmakar · 2024 · Exploration of Immunology
  36. SARS-CoV-2 seroprevalence and antibody trends in vaccinated, multi-ethnic healthcare employees
    Beh C.C. · 2021 · Tropical biomedicine
  37. A comparison of conventional and advanced electroanalytical methods to detect SARS-CoV-2 virus: A concise review
    Pattan‐Siddappa Ganesh, Sang‐Youn Kim · 2022 · Chemosphere
  38. Longitudinal Neutralization Activities on Authentic Omicron Variant Provided by 3 Doses of BBIBP-CorV Vaccination During One Year
    Dan‐yun Lai, Jun‐biao Xue, Ping He, He‐wei Jiang, Li Yang, Ming‐liang Ma, Wei Hong, Junping Yu, Hongping Wei, Sheng‐ce Tao · 2022 · PROTEOMICS
  39. The coverage of SARS-CoV-2 vaccination and the willingness to receive the SARS-CoV-2 variant vaccine among employees in China
    Xiru Zhang, Zhi-Ju Li, Qi Fu, Jindong Wang, Qingmei Huang, Wei-Qi Song, Xiaoyu Xu, Zhihao Li, Chen Mao · 2023 · BMC Public Health
  40. Durable protection against SARS-CoV-2 Omicron induced by an adjuvanted subunit vaccine
    Prabhu S. Arunachalam, Yupeng Feng, Usama Ashraf, Mengyun Hu, Venkata Viswanadh Edara, Veronika I. Zarnitsyna, Pyone P. Aye, Nadia Golden, Kristyn Moore Green, Breanna Threeton et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  41. Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients
    Matilda Xinwei Lee, Siyu Peng, Ainsley Ryan Yan Bin Lee, Shi Yin Wong, Ryan Yong Kiat Tay, Jiaqi Li, Areeba Tariq, Claire Xin Yi Goh, Ying Kiat Tan, Benjamin Kye Jyn Tan et al. · 2023 · Annals of the Academy of Medicine Singapore
  42. Determining the Time of Booster Dose Based on the Half-Life and Neutralization Titers against SARS-CoV-2 Variants of Concern in Fully Vaccinated Individuals
    Yu-Ching Dai, Yen-Chia Lin, Lauren Lei Ching, Jih‐Jin Tsai, Kyle Masato Ishikawa, Wen-Yang Tsai, John J. Chen, Vivek R. Nerurkar, Wei‐Kung Wang · 2023 · Microbiology Spectrum
  43. Assessing the evolution of SARS-CoV-2 lineages and the dynamic associations between nucleotide variations
    Asmita Gupta, Reelina Basu, Murali Dharan Bashyam · 2023 · Access Microbiology
  44. Development of a novel medium throughput flow-cytometry based micro-neutralisation test for SARS-CoV-2 with applications in clinical vaccine trials and antibody screening
    Sophie R O’Reilly, Grace Kenny, Tamara Alrawahneh, Nathan Francois, Lili Gu, Matthew Angeliadis, Valentin de Masson d’Autume, Alejandro Garcia Leon, Eoin R. Feeney, Obada Yousif et al. · 2023 · PLoS ONE
  45. Novel compounds with dual inhibition activity against SARS-CoV-2 critical enzymes RdRp and human TMPRSS2
    Sameh S. M. Soliman, Alshaimaa M. Hamoda, Yogendra Nayak, Ahmed Mostafa, Rania Hamdy · 2024 · European Journal of Medicinal Chemistry
  46. Low-frequency CD8+ T cells induced by SIGN-R1+ macrophage-targeted vaccine confer SARS-CoV-2 clearance in mice
    Daisuke Muraoka, Ling-Moi Meng, Osamu Muto, Takaaki Nakatsukasa, Si-Tuo Deng, Chieko Takashima, Rui Yamaguchi, Shin-ichi Sawada, Haruka Hayakawa, Thi Thanh Ngan Nguyen et al. · 2024 · npj Vaccines
  47. Development of chimeric MrNV virus-like particles capable of binding to SARS-CoV-2-susceptible cells and reducing infection by pseudovirus variants
    Supawich Boonkua, Orawan Thongsum, Purimpuch Soongnart, Rueangtip Chantunmapitak, Somkid Jaranathummakul, Kitima Srisanga, Somluk Asuvapongpatana, Patompon Wongtrakoongate, Wattana Weerachatyanukul, Atthaboon Watthammawut et al. · 2024 · Scientific Reports
  48. Coding-Complete Genome Sequences of a Delta Subvariant (AY.33) of SARS-CoV-2 Obtained from Moroccan COVID-19 Patients
    Mouhssine Hemlali, Taha Chouati, Hamza Ghammaz, Marouane Melloul, Sanaâ Alaoui Amine, Safaa Rhoulam, Nadia Touil, Khalid Ennibi, Hicham Oumzil, M. Rhajaoui et al. · 2022 · Microbiology Resource Announcements
  49. Genetics, structure, transmission, epidemiology, immune response, and vaccine efficacies of the SARS‐CoV‐2 Delta variant: A comprehensive review
    Han Jacob Li, Chelsea‐Jane Arcalas, Junmin Song, Masoud Rahmati, Seoyeon Park, Ai Koyanagi, Seung Won Lee, Dong Keon Yon, Jae Il Shin, Lee Smith · 2022 · Reviews in Medical Virology
  50. Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia
    Diego Alejandro Álvarez-Díaz, Ana Luisa Muñoz, María T. Herrera-Sepúlveda, Pilar Tavera-Rodríguez, Katherine Laiton‐Donato, Carlos Franco-Muñoz, Héctor Alejandro Ruiz-Moreno, Marisol Galindo, Jenssy D. Catama, Andrea Bermúdez-Forero et al. · 2022 · Vaccines
  51. Expanding repertoire of SARS-CoV-2 deletion mutations contributes to evolution of highly transmissible variants
    AJ Venkatakrishnan, Praveen Anand, Patrick J. Lenehan, Pritha Ghosh, Rohit Suratekar, Eli Silvert, Colin Pawlowski, Abhishek Siroha, Dibyendu Roy Chowdhury, John Charles O’Horo et al. · 2023 · Scientific Reports
  52. Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients
    Ahmad Alcheikh, Griffith Boord Perkins, Phillippa A. Pucar, Amelia Cecchin, Cheng Sheng Chai, Matthew J. Tunbridge, Anouschka Akerman, Anupriya Aggarwal, Vanessa Milogiannakis, Stuart Grant Turville et al. · 2023 · Blood Cancer Journal
  53. COVID-19 infection among healthcare workers in an oncology hospital
    Gülşen İskender, Duygu Mert, Zühal Avşar, Servet Kölgelier, Mustafa Ertek · 2023 · The Journal of Infection in Developing Countries
  54. Kinetics of Neutralizing Antibody Responses Against SARS-CoV-2 Delta Variant in Patients Infected at the Beginning of the Pandemic
    Pyoeng Gyun Choe, Yuri Kim, Euijin Chang, Chang Kyung Kang, Nam Joong Kim, Nam‐Hyuk Cho, Wan Beom Park, Myoung‐don Oh · 2022 · Journal of Korean Medical Science
  55. Neutralization assays for SARS-CoV-2
    Labanya Mukhopadhyay, Nivedita Gupta, Pragya Dhruv Yadav, Neeraj Aggarwal · 2022 · The Indian Journal of Medical Research
  56. Mild reinfection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta variant: First case report from Indonesia
    Naniek Isnaini, Yan Mardian, Dewi Lokida, Fajar Budiono, Deni P. Butar-butar, Dona Arlinda, Gustiani Salim, Herman Kosasih, Wahyu Nawang Wulan, Jacqueline Perodin et al. · 2022 · Frontiers in Medicine
  57. Loss of Pfizer (BNT162b2) Vaccine-Induced Antibody Responses Against the SARS-CoV-2 Omicron Variant in Adolescents and Adults
    Sneh Lata Gupta, Grace E. Mantus, Kelly E. Manning, Madison Leigh Ellis, Mit Patel, Caroline Rose Ciric, Austin Lu, Jackson S. Turner, Jane A. O’Halloran, Rachael M. Presti et al. · 2022 · SSRN Electronic Journal
  58. Longitudinal analysis of SARS-CoV-2 reinfection reveals distinct kinetics and emergence of cross-neutralizing antibodies to variants of concern
    Antonio Facciuolo, Jill van Kessel, Andrea Kroeker, Mingmin Liao, Jocelyne M. Lew, Darryl Falzarano, Alyson A. Kelvin, Volker Gerdts, Scott Napper · 2023 · Frontiers in Microbiology
  59. Human angiotensin-converting enzyme 2–specific antisense oligonucleotides reduce infection with SARS-CoV-2 variants
    Tong Lu, Chengcheng Zhang, Zhengqi Li, Yi Zhi Wei, Anne Sadewasser, Yan Yan, Lin Sun, Jian Li, Yihui Wen, Shimin Lai et al. · 2024 · Journal of Allergy and Clinical Immunology
  60. Enhanced D614G and Omicron Variants Antibody Persistence in Infants at 2 Months of Age Following Maternal mRNA Booster Vaccination During Pregnancy or Postpartum
    Flor M. Muñoz, Richard H. Beigi, Christine M. Posavad, Clifton W. Kelly, Martina L. Badell, Katherine E. Bunge, Mark J. Mulligan, Lalitha Parameswaran, Barbra A. Richardson, Courtney Olson‐Chen et al. · 2024 · The Pediatric Infectious Disease Journal
  61. Key Points of Technical Review for the Registration of Sars-Cov-2 Nucleic Acid Tests in China
    Hongran Li, Tong Jiao, Peirong Wang, Juanjuan An, Gang Deng, Lei Sun, Jinchun Dong · 2021 · Bioanalysis
  62. Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave
    Yu-Ching Dai, Yen-Chia Lin, Lauren Lei Ching, Alanna C. Tseng, Yujia Qin, Vivek R. Nerurkar, Wei‐Kung Wang · 2022 · Frontiers in Medicine
  63. Investigating the rise of Omicron variant through genomic surveillance of SARS-CoV-2 infections in a highly vaccinated university population
    Ilinca I. Ciubotariu, Rebecca Penrose Wilkes, Jobin Jose Kattoor, Erin N. Christian, Giovanna Carpi, Andrew Kitchen · 2024 · Microbial Genomics
  64. COVID-19 Vaccines
    Serkan Aydemir, Hatice Rümeysa Selvi, Rıdvan Dumlu, Secil Gunher Arica, Funda Şimşek · 2021 · European Archives of Medical Research
  65. Robust humoral and cellular immune responses in long-term convalescent COVID-19 individuals following one-dose SARS-CoV-2 inactivated vaccination
    Boyun Liang, Tiandan Xiang, Hua Wang, Ziwei Li, Xufeng Quan, Xuemei Feng, Sumeng Li, Sihong Lu, Lei Fan, Ling Xu et al. · 2022 · Frontiers in Immunology
  66. Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines
    Adam Nicolas Pelletier, Rafick‐Pierre Sékaly, Jeffrey Alan Tomalka · 2021 · Current Opinion in Virology
  67. Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike
    Patrick C. Wilson, Siriruk Changrob, Yanbin Fu, Jenna J. Guthmiller, Peter Halfmann, Lei Li, Christopher T. Stamper, Haley L. Dugan, Molly A. Accola, William M. Rehrauer et al. · 2021 · Research Square
  68. Active immunization by COVID-19 mRNA vaccine results in rapid antibody response and virus reduction in breakthrough infection by Delta (B.1.617.2)
    Yosuke Hirotsu, Toshiharu Tsutsui, Yumiko Kakizaki, Yoshihiro Miyashita, Fumiaki Iwase, Makoto Maejima, Hiroki Sugiura, Hitoshi Mochizuki, Masao Omata · 2021 · Research Square
  69. Monocyte-eosinophil signaling axis promotes vaccine-mediated protection against SARS-CoV-2
    Kathryn M. Moore, Stephanie L. Foster, Meenakshi Kar, Katharine A. Floyd, Elizabeth J. Elrod, Mary E. K. Williams, Jacob W. Vander Velden, Madison Leigh Ellis, Ansa A. Malik, Bushra Wali et al. · 2025 · PLoS Pathogens
  70. The safety, reactogenicity, and immunogenicity of the self-amplifying mRNA COVID-19 vaccine GRT-R910 as a booster in healthy adults
    Jennifer A. Whitaker, Paulina Alejandra Rebolledo, Getahun Abate, Tara M Babu, Nadine G. Rouphael, Anna P. Wald, Hana M. El Sahly, Karin U. Jooss, Meghan G. Hart, Mat Makowski et al. · 2026 · Vaccine
  71. Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses
    Sanjeev Kumar, Lilin Lai, Madison Ellis, Anamika B. Patel, Devyani Joshi, Jacob W. Vander Velden, Jana Abu Faraj, Sonia Wimalasena, Ramitha R. Pallavi, Jad Iriss et al. · 2026 · Journal of Virology
  72. Delta (B.1.617.2) inactivated vaccine candidate elicited neutralizing antibodies to SARS-CoV-2 and circulating variants in rhesus macaques
    Yanjun Zhang, Haiyan Mao, Li Ju, Jianhua Li, Chen Huang, Jiaxuan Li, Minglei Chu, Fengbo Xue, Linhui Wang, Zhongbiao Fang et al. · 2023 · Virologica Sinica
  73. A wild boar cathelicidin peptide derivative inhibits severe acute respiratory syndrome coronavirus-2 and its drifted variants
    Troy Alexander von Beck, Karla Navarrete, Nicholas A. Arce, Mu Gao, Gordon A. Dale, Meredith E. Davis-Gardner, Katharine A. Floyd, Luis Mena Hernandez, Nikita Mullick, Abigail Vanderheiden et al. · 2023 · Scientific Reports
  74. Application of Omics and Bioinformatics Technologies in Response to COVID-19 Pandemic
    Abebe Mengesha Aga, Adugna Abdi Woldesemayat · 2024 · Molecular and Cellular Biomedical Sciences
  75. Lessons from COVID‐19: Aspects of prevention, therapeutics, and diagnostics against SARS‐CoV‐2 with special focus on JN.1 and XBB sublineages
    Puja Jaishwal, Upagya Gyaneshwari, Kisalay Jha, Brijesh Pandey, Thakur Prasad Yadav, Satarudra Prakash Singh · 2024 · MedComm – Future Medicine
  76. Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways
    Matthew Gagné, Barbara J. Flynn, Christopher Cole Honeycutt, Dillon R. Flebbe, Shayne F. Andrew, Samantha J. Provost, Lauren McCormick, Alex Van Ry, Elizabeth E. McCarthy, John-Paul M. Todd et al. · 2024 · Nature Communications
  77. Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity
    Alberto Moreno, Kelly E. Manning, Maryam I. Azeem, Ajay K. Nooka, Madison Leigh Ellis, Renee Julia Manalo, Jeffrey M. Switchenko, Bushra Wali, Jonathan L. Kaufman, Craig C. Hofmeister et al. · 2024 · npj Vaccines
  78. Future of the Coronavirus Disease-2019 Pandemic
    Sougat Ray, C Sudeep Naidu, Kiran Kumar Maramraj, Naveen Chawla, Shruti Vashisht, Kaushik Roy, Athul N Gopinath · 2021 · Journal of Marine Medical Society
  79. Serum from COVID-19 patients early in the pandemic shows limited evidence of cross-neutralization against variants of concern
    Amanda J. Griffin, Kyle Lee O’Donnell, Kyle Shifflett, John‐Paul Lavik, Patrick M. Russell, Michelle K. Zimmerman, Ryan F. Relich, Andrea Marzi · 2022 · Scientific Reports
  80. Design and Immunogenicity of SARS-CoV-2 DNA Vaccine Encoding RBD-PVXCP Fusion Protein
    Dmitri Dormeshkin, Mikalai Katsin, Maria V. Stegantseva, Sergey Golenchenko, Michail A. Shapira, Simon Dubovik, Dzmitry V. Lutskovich, Anton Kavaleuski, Alexander Meleshko · 2023 · Vaccines
  81. The neutralization of B.1.617.1 and B.1.1.529 sera from convalescent patients and BBIBP-CorV vaccines
    Xinyi Yang, Yuqi Zhu, Jingna Xun, Jun Liu, Qing Wen, Yixiao Lin, Xiaoting Shen, Jun Chen, Songhua Yuan, Xiaying Zhao et al. · 2022 · iScience
  82. Monobiotinylated Proteins Tethered to Microspheres for Detection of Antigen-Specific Serum Antibodies
    Caleb S. Whitley, Thomas C. Mitchell · 2022 · Journal of Biological Methods
  83. Absence of antibody responses to SARS-CoV-2 N protein in COVID-19 vaccine breakthrough cases
    Luan D. Vu, Shonta Wallace, Anh Phan, Rebecca C. Christofferson, Erik A. Turner, Sean Parker, Karen E Elkind-Hirsch, Darrell Landry, Austin Stansbury, Rebecca Rose et al. · 2022 · Experimental Biology and Medicine
  84. Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac
    Diego A. Díaz-Dinamarca, Simone Cárdenas-Cáceres, Nicolás A. Muena, Pablo Díaz, Gisselle N. Barra, Rodrigo Puentes, Daniel F. Escobar, Michal Díaz-Samirin, Natalia T. Santis-Alay, Cecilia Canales et al. · 2024 · Vaccines
  85. The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines
    Juan Manuel Carreño, Ariel J. Raskin, Gagandeep Singh, Johnstone Tcheou, Hisaaki Kawabata, Charles Gleason, Komal Srivastava, Vladimir I. Vigdorovich, Nicholas Dambrauskas, Sneh Lata Gupta et al. · 2022 · medRxiv
  86. Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine — An Interim Analysis
    Evan J. Anderson, Lisa A. Jackson, Nadine Rouphael, Alicia T. Widge, David C. Montefiori, Nicole A. Doria‐Rose, Mehul S. Suthar, Kristen W. Cohen, Sarah E. O’Connell, Mat Makowski et al. · 2022 · Research Square
  87. A replicon RNA vaccine induces durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned
    Megan A. O’Connor, David W. Hawman, Kimberly D. Meade-White, Shanna S. Leventhal, Wenjun Song, Samantha Randall, Jacob F. Archer, Thomas B. Lewis, Brieann Brown, Naoto Iwayama et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  88. Antigenic characterization of SARS-CoV-2 variants BA.3.2.1 and BA.3.2.2 in three animal models
    Samuel A. Turner, Joey Olivier, Madison L Ellis, Katharine A. Floyd, Lilin Lai, Suzanne M. Scheaffer, Ionsei Hastings, Tamarand L. Darling, Blake A. Miller, Charmy J Patel et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  89. Unlocking the puzzle: non-defining mutations in SARS-CoV-2 proteome may affect vaccine effectiveness
    Eugenia Ulzurrun, Ana Grande-Pérez, Daniel del Hoyo, César Guevara, Carmen Gil, Carlos Óscar S. Sorzano, Nuria Eugenia Campillo · 2024 · Frontiers in Public Health
  90. A multicentric study to correlate severity of disease and vaccine in COVID-19 pandemic
    Ankita Rushik Patel, Rekha Nilesh Solanki, Heena Sunil Chhanwal, Viral Dave, Arpit Chelabhai Prajapati, Mansi Maulik Patel · 2022 · Ain-Shams Journal of Anaesthesiology
  91. Immune responses to vaccines: from classical to systems approaches
    Joao L. L. C. Azevedo, Viviane Schuch, João Marcos Maia Silva, André Guilherme Costa Martins, Luiz Gustavo Gardinassi, Helder Imoto Nakaya, Simone Gonçalves Fonseca · 2022 · Elsevier eBooks
  92. Predictive biomarkers and specific immune responses of COVID-19 mRNA vaccine in patients with cancer: prospective results from the CACOV-VAC trial
    Laurie Spehner, Émeline Orillard, Antoine Falcoz, Quentin Lepiller, Adeline Bouard, Hamadi Almotlak, Stefano Chong Hun Kim, Elsa Curtit, Guillaume Meynard, Marine Jary et al. · 2023 · BMJ Oncology
  93. Systematic Genomic Surveillance of SARS-CoV-2 at Xiamen International Airport and the Port of Xiamen Reveals the Importance of Incoming Travelers in Lineage Diversity
    Ruiluan You, Ruotong Wu, Xijing Wang, Rao Fu, Ningshao Xia, Yixin Chen, Kunyu Yang, Junyu Chen · 2024 · Viruses
  94. Immunogenicity of an adenovirus-vectored bivalent vaccine against wild type SARS-CoV-2 and Omicron variants in a murine model
    Yuanyuan Ji, Xiuwen Sui, Wei Miao, Chang Wang, Qing Wang, Zhuojun Duan, Bochao Wei, Dan Wu, Menghan Wei, Juan Shao et al. · 2024 · Vaccine
  95. An Overview of COVID-19 and Its Vaccines
    Nahid Rehman, Anjana Pandey · 2021 · Biology Bulletin Reviews
  96. A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity
    Yuki Moriyama, Masahiro Ishikane, Mikako Ueno, Akihiro Matsunaga, Yukihito Ishizaka, Takeshi Arashiro, Takayuki Kanno, Tadaki Suzuki, Kenjiro Kimura · 2022 · Journal of Infection and Chemotherapy
  97. BNT162b2-Elicited Neutralization of Delta Plus, Lambda, and Other Variants
    Jianying Liu, Yang Liu, Hongjie Xia, Jing Zou, Scott C. Weaver, Kena A. Swanson, Hui Cai, Mark W. Cutler, David Cooper, Alexander Muik et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  98. Impaired Neutralisation of SARS-CoV-2 Delta Variant in Vaccinated Patients With B Cell Chronic Lymphocytic Leukaemia
    Helen Parry, Graham McIlroy, Rachel K. Bruton, Sarah L. Damery, Grace B. Tyson, Nicola A. Logan, Christopher Davis, Brian J. Willett, Jianmin Zuo, Myah Ali et al. · 2021 · SSRN Electronic Journal
  99. Covid‐19: Medical, Social and Psychological Aspects
    Zohar Lederman · 2021 · Wiley eBooks
  100. Systems immune profiling of variant-specific vaccination against SARS-CoV-2
    Lei Peng, Jonathan Joon-Young Park, Zhenhao Fang, Xiaoyu Zhou, Matthew B. Dong, Qiancheng Xiong, Chenxiang Lin, Sidi Chen · 2021 · bioRxiv (Cold Spring Harbor Laboratory)